AGLE - Aeglea BioTherapeutics Inc Stock Price, Fair Value and News

27.60USD-0.08 (-0.29%)Market Closed

Market Summary

USD27.60-0.08

Market Closed

-0.29%

AGLE Stock Price

View Fullscreen

AGLE RSI Chart

AGLE Valuation

Market Cap

994.2M

Price/Earnings (Trailing)

-2.93

Price/Sales (Trailing)

1.1K

EV/EBITDA

-2.38

Price/Free Cashflow

-9.95

AGLE Price/Sales (Trailing)

AGLE Profitability

EBT Margin

-38241.08%

Return on Equity

-184.11%

Return on Assets

-99.1%

Free Cashflow Yield

-10.05%

AGLE Fundamentals

AGLE Revenue

Revenue (TTM)

886.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

AGLE Earnings

Earnings (TTM)

-338.8M

Earnings Growth (Yr)

-235.67%

Earnings Growth (Qtr)

-57.53%

Breaking Down AGLE Revenue

Last 7 days

14.0%

Last 30 days

51.4%

Last 90 days

158.0%

Trailing 12 Months

122.8%

How does AGLE drawdown profile look like?

AGLE Financial Health

Current Ratio

10.68

AGLE Investor Care

Shares Dilution (1Y)

1282.02%

Diluted EPS (TTM)

-49.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.2M	1.2M	1.1M	886.0K
2022	20.1M	7.0M	5.8M	2.3M
2021	5.5M	9.9M	14.3M	18.7M
2020	1.5M	1.7M	1.1M	0
2019	0	3.0M	1.2M	0
2018	5.7M	6.6M	5.4M	3.9M
2017	4.8M	4.9M	5.0M	5.2M
2016	6.9M	4.9M	5.0M	4.6M
2015	0	0	0	6.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aeglea BioTherapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 24, 2023	fairmount funds management llc	acquired	-	-	3,435,480	-
Nov 24, 2023	turtle cameron	acquired	-	-	723,440	chief executive officer
Aug 25, 2022	souza marcio	bought	50,472	0.5608	90,000	-
Jun 08, 2022	hanley jr. michael conick	bought	20,022	0.71	28,200	chief commercial officer
Mar 16, 2022	quinn anthony g.	bought	187,705	2.344	80,079	president & ceo
Mar 15, 2022	quinn anthony g.	bought	78,942	1.8611	42,417	president & ceo
Mar 14, 2022	quinn anthony g.	bought	130,221	1.93	67,472	president & ceo
Mar 11, 2022	quinn anthony g.	bought	71,779	2.064	34,777	president & ceo
Mar 11, 2022	alspaugh jonathan	bought	156,000	2.08	75,000	chief financial officer
Dec 13, 2021	shanafelt armen	bought	53,600	3.65	14,685	-

Which funds bought or sold AGLE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Assenagon Asset Management S.A.	new	-	2,442,690	2,442,690	0.01%
Apr 15, 2024	Legato Capital Management LLC	new	-	434,602	434,602	0.05%
Mar 11, 2024	VANGUARD GROUP INC	added	19.26	443,685	848,878	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	added	3,113	55,102,100	56,095,700	1.25%
Feb 15, 2024	Virtus ETF Advisers LLC	new	-	134,263	134,263	0.09%
Feb 15, 2024	BARCLAYS PLC	new	-	979,000	979,000	-%
Feb 14, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	new	-	21,520,000	21,520,000	0.04%
Feb 14, 2024	Blackstone Inc.	new	-	430,206	430,206	-%
Feb 14, 2024	CITADEL ADVISORS LLC	added	494	11,221,900	12,410,800	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-5,000	-	-%

Are Funds Buying or Selling AGLE?

Are funds buying AGLE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AGLE

No. of Funds

Unveiling Aeglea BioTherapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 23, 2024	avoro capital advisors llc	5.1%	1,839,138	SC 13G/A
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	2.5%	887,076	SC 13G/A
Feb 14, 2024	perceptive advisors llc	7.2%	2,606,679	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	0.0%	0	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	0%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	6.2%	2,232,760	SC 13G
Feb 14, 2024	rock springs capital management lp	0%	0	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	5.9%	2,125,597	SC 13G
Feb 14, 2024	logos global management lp	0.4%	150,000	SC 13G/A

Recent SEC filings of Aeglea BioTherapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	8-K	Current Report
Apr 25, 2024	SC 13D/A	13D - Major Acquisition
Apr 23, 2024	SC 13G/A	Major Ownership Report
Apr 19, 2024	S-1	Initial Public Offering
Apr 02, 2024	ARS	ARS
Apr 01, 2024	EFFECT	EFFECT
Apr 01, 2024	EFFECT	EFFECT
Apr 01, 2024	DEF 14A	DEF 14A
Mar 27, 2024	POS AM	POS AM

Peers (Alternatives to Aeglea BioTherapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.92	14.56	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Aeglea BioTherapeutics Inc News

Latest updates

Aeglea BioTherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q3	2020Q2	2020Q1	2019Q3	2019Q2	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-	-	-	688,000	198,000	168,000	174,000	625,000	1,362,000	3,644,000	1,399,000	13,696,000	6,892,000	88,000	161,000	300,000	585,000	619,000	12,000	-	2,378,000	1,510,000
Operating Expenses	150.4%	45,914,000	18,337,000	159,934,000	19,004,000	19,330,000	18,929,000	23,048,000	25,803,000	24,086,000	21,692,000	20,401,000	18,209,000	18,123,000	21,560,000	19,022,000	22,146,000	18,622,000	15,305,000	12,243,000	12,048,000	9,755,000
S&GA Expenses	63.9%	14,072,000	8,584,000	12,062,000	5,228,000	5,079,000	6,952,000	7,675,000	8,825,000	7,304,000	6,839,000	6,822,000	6,354,000	5,672,000	4,691,000	4,460,000	4,307,000	3,816,000	3,507,000	3,314,000	2,926,000	2,885,000
R&D Expenses	-	-	-	-	13,776,000	14,251,000	11,977,000	15,373,000	16,978,000	16,782,000	14,853,000	13,579,000	11,855,000	12,451,000	16,869,000	14,562,000	17,839,000	14,806,000	11,798,000	8,929,000	9,122,000	6,870,000
EBITDA Margin	-37.1%	-381	-278	-220	-65.61	-35.38	-14.47	-12.21	-3.50	-3.42	-20.38	-20.42	-20.47	-	-	-	-	-	-	-	-	-
Income Taxes	-100.0%	-	3,000	7,000	-36,000	51,000	-209,000	9,000	-	23,000	26,000	92,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-57.5%	-63,180,000	-40,104,000	-217,074,000	-18,458,000	-18,771,000	-18,443,000	-22,314,000	-24,436,000	-20,423,000	-20,281,000	-6,738,000	-	-18,033,000	-21,418,000	-	-	-	-	-	-	-
EBT Margin	-36.9%	-382	-279	-222	-66.94	-36.05	-14.75	-12.44	-3.58	-3.50	-20.77	-20.77	-20.77	-	-	-	-	-	-	-	-	-
Net Income	-57.5%	-63,180,000	-40,107,000	-217,081,000	-18,422,000	-18,822,000	-18,234,000	-22,323,000	-24,436,000	-20,446,000	-20,307,000	-6,830,000	-18,218,000	-18,033,000	-21,418,000	-18,728,000	-21,573,000	-18,019,000	-14,898,000	-11,917,000	-9,414,000	-8,119,000
Net Income Margin	-36.9%	-382	-279	-221	-66.78	-35.99	-14.72	-12.45	-3.58	-3.51	-17.48	-16.90	-20.64	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-31,036,000	-	-16,643,000	-17,634,000	-18,140,000	-15,069,000	-20,673,000	-26,300,000	-19,268,000	-17,093,000	2,052,000	-19,980,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	64.9%	342	207	244	52.00	71.00	92.00	107	83.00	110	129	147	164	162	156	173	65.00	83.00	100	117	129	78.00
Current Assets	65.8%	342	206	240	44.00	62.00	82.00	97.00	73.00	99.00	118	134	151	150	144	162	54.00	75.00	93.00	110	127	77.00
Cash Equivalents	108.5%	189	91.00	3.00	35.00	35.00	41.00	37.00	15.00	17.00	25.00	35.00	80.00	92.00	54.00	66.00	13.00	19.00	25.00	25.00	86.00	22.00
Net PPE	-	-	-	-	3.00	3.00	4.00	4.00	4.00	5.00	5.00	5.00	6.00	6.00	5.00	5.00	4.00	2.00	1.00	1.00	1.00	1.00
Liabilities	11.8%	73.00	66.00	254	19.00	21.00	24.00	23.00	22.00	26.00	27.00	28.00	40.00	22.00	19.00	21.00	22.00	23.00	20.00	18.00	12.00	10.00
Current Liabilities	-28.7%	32.00	45.00	232	13.00	15.00	18.00	16.00	16.00	20.00	20.00	21.00	32.00	16.00	14.00	16.00	17.00	18.00	15.00	13.00	12.00	10.00
Shareholder's Equity	-	184	-	-	34.00	50.00	68.00	84.00	62.00	84.00	102	119	124	140	136	152	43.00	60.00	80.00	100	116	67.00
Retained Earnings	-9.0%	-764	-701	-661	-444	-425	-406	-388	-366	-341	-321	-301	-294	-276	-253	-235	-213	-195	-173	-152	-134	-116
Additional Paid-In Capital	67.4%	763	456	454	478	476	475	473	428	426	423	420	418	416	390	387	257	255	253	252	250	184
Shares Outstanding	790.6%	36.00	4.00	3.00	3.00	3.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	26.00	-	-	-	30.00	-	-	-	337	-	-	-	386	-	-	-	178	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	10.3%	-31,036	-34,597	-16,643	-17,634	-18,140	-15,068	-20,673	-26,263	-19,268	-17,000	2,082	-19,530	-17,132	-17,536	-19,413	-21,694	-16,294	-17,208	-16,383	-15,807	-7,200
Share Based Compensation	260.9%	17,270	4,785	1,911	1,709	1,427	1,566	2,017	2,101	2,094	2,107	2,080	1,757	1,612	1,696	1,600	1,348	1,184	1,366	1,245	1,081	1,377
Cashflow From Investing	63.9%	-35,272	-97,631	6,760	17,750	14,000	16,499	750	25,759	9,663	5,777	-47,359	9,300	28,620	5,784	-56,761	14,753	10,326	16,012	-42,013	13,936	-2,132
Cashflow From Financing	1405.6%	163,606	-12,531	209,992	10.00	-8.00	-130	42,804	12.00	80.00	1,143	-192	362	24,679	258	129,293	282	676	311	-319	65,055	17,261

AGLE Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Revenue:

Total revenue

$ 886

$ 2,329

$ 18,739

Operating expenses:

Research and development

^[1]

89,504

58,579

57,069

General and administrative

39,946

28,531

27,319

Acquired in-process research and development

130,188

Gain on sale of in-process research and development asset

(16,449)

Total operating expenses

243,189

87,110

84,388

Loss from operations

(242,303)

(84,781)

(65,649)

Other (expense) income:

Interest income

6,147

837

111

Other expense, net

(19,130)

(7)

(122)

Total other (expense) income

(96,513)

830

(11)

Loss before income tax expense

(338,816)

(83,951)

(65,660)

Income tax benefit (expense)

136

(141)

Net loss

$ (338,790)

$ (83,815)

$ (65,801)

Net loss per share, basic (in dollars per share)

$ (49.12)

$ (24.86)

$ (25.02)

Net loss per share, diluted (in dollars per share)

$ (49.12)

$ (24.86)

$ (25.02)

Weighted-average common shares outstanding, basic (in shares)

6,897,065

3,371,231

2,629,784

Weighted-average common shares outstanding, diluted (in shares)

6,897,065

3,371,231

2,629,784

Forward Contract Liability

Other (expense) income:

Change in fair value of forward contract liability

$ (83,530)

$ 0

License

Revenue:

Total revenue

12,000

Development fee and royalty

Revenue:

Total revenue

$ 886

$ 2,329

$ 6,739

[1]	Includes $48.5 million in related party expenses for the year ended December 31, 2023 and no related party expenses for the year ended months ended December 31, 2022 and 2021.

AGLE Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 188,893	$ 34,863
Marketable securities	150,384	20,848
Development receivables	0	375
Prepaid expenses and other current assets	2,251	6,172
Total current assets	341,528	62,258
Restricted cash	322	1,553
Property and equipment, net	0	3,220
Operating lease right-of-use assets	0	3,430
Other non-current assets	9	683
TOTAL ASSETS	341,859	71,144
CURRENT LIABILITIES
Accounts payable	896	677
CVR liability	1,390	0
Operating lease liabilities	0	625
Deferred revenue	0	517
Accrued and other current liabilities	13,108	12,837
Related party accounts payable and other current liabilities	16,584	0
Total current liabilities	31,978	14,656
Non-current CVR liability	41,310	0
Non-current operating lease liabilities	0	4,004
Deferred revenue, net of current portion	0	2,179
TOTAL LIABILITIES	73,288	20,839
Commitments and Contingencies (Note 9)
Series B non-voting convertible preferred stock, $0.0001 par value; 150,000 and no shares authorized as of December 31, 2023 and December 31, 2022, respectively; 150,000 and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.	84,555	0
STOCKHOLDERS’ EQUITY
Common stock, $0.0001 par value; 400,000,000 and 20,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 36,057,109 shares and 2,614,014 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.	10	6
Additional paid-in capital	763,191	475,971
Accumulated other comprehensive income (loss)	302	(48)
Accumulated deficit	(764,414)	(425,624)
TOTAL STOCKHOLDERS’ EQUITY	184,016	50,305
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY	341,859	71,144
Series A Non-Voting Convertible Preferred Stock
STOCKHOLDERS’ EQUITY
Preferred stock	184,927	0
Preferred Stock
STOCKHOLDERS’ EQUITY
Preferred stock	$ 0	$ 0

About Aeglea BioTherapeutics Inc

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

WEBSITE	aeglea.com
INDUSTRY	Biotechnology
EMPLOYEES	14

Aeglea BioTherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aeglea BioTherapeutics Inc? What does AGLE stand for in stocks?

AGLE is the stock ticker symbol of Aeglea BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aeglea BioTherapeutics Inc (AGLE)?

As of Thu Feb 29 2024, market cap of Aeglea BioTherapeutics Inc is 994.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers. The fair value of Aeglea BioTherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aeglea BioTherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGLE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aeglea BioTherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGLE is over valued or under valued. Whether Aeglea BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Aeglea BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGLE.

What is Aeglea BioTherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, AGLE's PE ratio (Price to Earnings) is -2.93 and Price to Sales (PS) ratio is 1.12 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGLE PE ratio will change depending on the future growth rate expectations of investors.